艾迪注射液联合放疗治疗鼻咽癌56例临床观察  

Clinical observation on Aidi injection combined with radiotherapy for nasopharyngeal carcinoma in 56 cases

作　　者：张传建[1] 刘化勇[1] 

机构地区：[1]临沂市人民医院放疗中心,山东临沂276003

出　　处：《肿瘤防治杂志》2005年第7期541-542,共2页China Journal of Cancer Prevention and Treatment

摘　　要：将56例鼻咽癌患者按入院先后顺序,分为艾迪注射液联合放疗(观察组)28例和单纯放疗28例(对照组)。两组患者均采用常规分割放疗,观察组在开始放疗同时应用艾迪注射液。结果观察组有效者26例(92.9%),对照组为25例(89.3%),两组比较差异无统计学意义,P=0.6393。观察组生活质量(KPS评分)好转为16例(57.1%),对照组为8例(28.6%),P=0.0308;观察组骨髓抑制为8例(28.6%),对照组为16例(57.1%),P=0.0308;观察组口腔黏膜反应为19例(67.9%),对照组为27例(96.4%),P=0.0052。初步研究结果显示,艾迪注射液配合放疗能减毒增效,提高患者生活质量。Fifty-six patients were randomly divided into the observation group (Group A) and control group (Group B), 28 patients were treated with Aidi injection combined with radiotherapy (Group A) and 28 patients were treated with radiotherapy only (Group B). Results: The overall response rates (CR+PR) were 26 cases (92.9%) in the observation group and 25 cases (89.3%) in the control group, P=0.639 3, there was no significant difference. Quality of life (KPS) improved in 16 cases (57.1%) in the observation group and 8 cases (28.6%) in the control group,P=0.030 8; myelosuppression was found in 8 cases (28.6%) in the observation group and 16 case (57.1%) in the control group,P=0.030 8. The side effects in oral cavity mucous membrane was found in 19 cases (67.9%) in the observation group and 27 cases (96.4%) in the control, P=0.005 2. No patients couldn’t accept toxicity and prolong radiotherapy time in the observation group. Conclusions: Aidi injection combined with radiotherapy for nasopharyngeal can improve clinical efficacy and quality of life, mainly reduce side effects.

关 键 词：鼻咽肿瘤/药物疗法 鼻咽肿瘤/放射疗法 抗肿瘤药/治疗应用 

分 类 号：R739.63[医药卫生—肿瘤]